TP53 and hereditary disease: Successful clinical application of CRISPR/Cas9 for genetic disorders, such as sickle cell disease and β-thalassemia, validated the therapeutic strategy for genome editing and paved the way for targeting cancer and hereditary diseases associated with mutated or impaired TP53 gene.